Trevi Therapeutics Net Worth
Trevi Therapeutics Net Worth Breakdown | TRVI |
Trevi Therapeutics Net Worth Analysis
Trevi Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Trevi Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Trevi Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Trevi Therapeutics' net worth analysis. One common approach is to calculate Trevi Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Trevi Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Trevi Therapeutics' net worth. This approach calculates the present value of Trevi Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Trevi Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Trevi Therapeutics' net worth. This involves comparing Trevi Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Trevi Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Trevi Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Trevi Therapeutics' net worth research are outlined below:
| Trevi Therapeutics is way too risky over 90 days horizon | |
| Trevi Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (47.91 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Trevi Therapeutics currently holds about 77.86 M in cash with (38.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82. | |
| Trevi Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 82.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Trevi Therapeutics Shares Gap Up After Earnings Beat |
Trevi Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Trevi Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Trevi Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Trevi Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Trevi Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Trevi Therapeutics backward and forwards among themselves. Trevi Therapeutics' institutional investor refers to the entity that pools money to purchase Trevi Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Opaleye Management Inc | 2024-12-31 | 2.3 M | Mccormack Advisors International | 2024-12-31 | 1.4 M | Geode Capital Management, Llc | 2024-12-31 | 1.3 M | Vr Adviser, Llc | 2024-12-31 | 1.3 M | Logos Global Management Lp | 2024-12-31 | 1.2 M | Citadel Advisors Llc | 2024-12-31 | 1.2 M | State Street Corp | 2024-12-31 | 1.2 M | Checkpoint Capital Lp | 2024-12-31 | 1.1 M | Rosalind Advisors, Inc. | 2024-12-31 | 1.1 M | Nea Management Company, Llc | 2024-12-31 | 11.4 M | Viking Global Investors Lp | 2024-12-31 | 4.4 M |
Follow Trevi Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 590.71 M.Market Cap |
|
Project Trevi Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.43) | (0.45) | |
| Return On Capital Employed | (0.51) | (0.54) | |
| Return On Assets | (0.43) | (0.45) | |
| Return On Equity | (0.48) | (0.50) |
When accessing Trevi Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Trevi Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Trevi Therapeutics' profitability and make more informed investment decisions.
Evaluate Trevi Therapeutics' management efficiency
Trevi Therapeutics has return on total asset (ROA) of (0.3215) % which means that it has lost $0.3215 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5259) %, meaning that it created substantial loss on money invested by shareholders. Trevi Therapeutics' management efficiency ratios could be used to measure how well Trevi Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.45. The current Return On Capital Employed is estimated to decrease to -0.54. As of now, Trevi Therapeutics' Net Tangible Assets are increasing as compared to previous years. The Trevi Therapeutics' current Non Currrent Assets Other is estimated to increase to about 323.5 K, while Total Assets are projected to decrease to under 63.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.99 | 1.14 | |
| Tangible Book Value Per Share | 0.99 | 1.14 | |
| Enterprise Value Over EBITDA | (7.44) | (7.07) | |
| Price Book Value Ratio | 4.18 | 4.39 | |
| Enterprise Value Multiple | (7.44) | (7.07) | |
| Price Fair Value | 4.18 | 4.39 | |
| Enterprise Value | 383.2 M | 402.4 M |
The leadership approach at Trevi Therapeutics' fosters a culture of excellence and accountability. Our analysis examines how this culture influences financial outcomes and stock valuation.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Trevi Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Trevi Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Trevi Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Trevi Therapeutics Corporate Filings
| 20th of March 2025 Other Reports | ViewVerify | |
8K | 18th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 12th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Trevi Therapeutics Earnings per Share Projection vs Actual
Trevi Therapeutics Corporate Management
| Farrell PharmD | Chief Officer | Profile | |
| Christopher Galletta | Controller Officer | Profile | |
| AFPM MD | Chief Officer | Profile | |
| Danine Summers | Vice Affairs | Profile | |
| Lisa Delfini | Chief Officer | Profile | |
| Jennifer Good | CEO, CoFounder | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trevi Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.